Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Single Sales/Supply Contract' amendment. It details a contract extension for the supply of Botulinum toxin to Evolus, Inc. Since this is a specific regulatory disclosure regarding a material business contract (a 'Major Business Matter' or 'Significant Contract' filing in the Korean market context), and it does not fit into the other specific categories like M&A or Dividend announcements, it falls under the general regulatory filing category.
2024-02-01 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of corporate actions related to share buybacks or treasury share management. According to the provided definitions, 'Transaction in Own Shares' (POS) is the most accurate classification for reports concerning the company buying back or selling its own shares, including the termination of trust contracts related to such activities.
2024-01-31 Korean
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details a specific business contract for the joint development, technology export, and commercialization of a pharmaceutical product (DWJ108U) with Zydus Worldwide DMCC. Since this is a specific corporate announcement regarding a material business contract that does not fit into the other specialized categories like M&A or Share Issues, it is classified as a general Regulatory Filing (RNS).
2023-12-11 Korean
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, the counterparty (JSC Pharmasyntez), the region (Russia/CIS), and the nature of the supply (Enavogliflozin). Since this is a specific corporate disclosure of a material contract that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2023-12-01 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Daewoong Co., Ltd. for the 3rd quarter of 2023. It contains detailed financial information, business descriptions, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status via Trust Agreement' (신탁계약등에의한취득상황보고서) filed by Daewoong Co., Ltd. to the Financial Supervisory Service. It details the company's share buyback activities conducted through a trust agreement with KB Securities. This type of filing, which reports the company's purchase of its own shares, falls under the category of 'Transaction in Own Shares'.
2023-11-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.